慢性阻塞性肺病（COPD）：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

市場概覽

• 西班牙市場（輕度至中度細分市場）預計將從約 2.19億美元成長到約 2.31億美元（年複合成長率約 0.5%）。
• 受非專利吸入療法和疾病流行率穩定的推動，以及突破性創新有限，成長仍然較為溫和。

慢性阻塞性肺病（COPD）概述

慢性阻塞性肺病（COPD）是全球慢性疾病發生率和死亡率的主要原因之一，也是目前全球主要死因之一。此疾病的特徵是由於慢性發炎、氣道重塑和肺實質進行性破壞而導致的持續性氣流受限。

病理學，慢性阻塞性肺病（COPD）包括小氣道狹窄、肺泡附著喪失和肺彈性下降，阻礙氣流，尤其是在呼氣時。這會導致氣體滯留、氣體交換減少和進行性呼吸功能障礙。

診斷可經由肺功能測定確診，支氣管擴張劑給藥後FEV1/FVC比值小於0.70提示氣流受限。然而，疾病的嚴重程度並非僅取決於氣流受限；症狀的嚴重程度（例如呼吸困難、咳嗽）和病情加重的頻率在臨床評估中發揮非常重要的作用。

現代慢性阻塞性肺病（COPD）管理採用多方面方法，結合肺功能分級、症狀負擔和急性惡化風險來確定治療策略。治療包括支氣管擴張劑（長效BETA2受體促效劑/長效抗膽鹼能藥物）、吸入性糖皮質激素（ICS）和支持性治療，目的是緩解症狀、預防急性惡化並提高生活品質。

主要亮點

• 慢性阻塞性肺病是一種慢性呼吸系統疾病，盛行率高，在全球造成嚴重的死亡負擔。
• 預計美國患有該疾病的人數將從約 2,810萬增加到約 3,300萬人（年複合成長率約 1.6%）。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

形式和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化在 32個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准和順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

主要企業

• SMSbiotech
• Haisco Pharmaceutical Group Co., Ltd.
• GlaxoSmithKline
• Hoffmann-La Roche
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Genentech, Inc.
• Verona Pharma plc
• Keymed Biosciences Co.Ltd
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Reistone Biopharma Company Limited
• Sanofi
• Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
• Eurofarma Laboratorios SA
• AstraZeneca
• Sunshine Guojian Pharmaceutical（Shanghai）Co., Ltd.
• Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
• Regend Therapeutics
• Nuance Pharma（shanghai）Co., Ltd
• Upstream Bio Inc.
• Bambusa Therapeutics
• Areteia Therapeutics
• Chia Tai Tianqing Pharmaceutical（Guangzhou）Co., Ltd.
• Anhui Hemay Pharmaceutical Co., Ltd
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Mabwell（Shanghai）Bioscience Co., Ltd.
• S-INFINITY Pharmaceuticals Co., Ltd
• Merck Sharp &Dohme LLC
• Mesoblast, Inc.
• Joincare Pharmaceutical Group Industry Co., Ltd
• Ganzhou Hemay Pharmaceutical Co., Ltd
• Chiesi Farmaceutici SpA
• Bun Yao Biotechnology Co., Ltd
• Generate Biomedicines
• Rise Therapeutics LLC
• AeroRx Therapeutics Inc.

目錄

第1章 主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要治療方法 - 概述及關鍵意見領袖見解
• 新興治療方法
• 重點
• 值得關注的後期新興治療方法 - 概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章 未滿足的需求與目標產品分析

• 主要未滿足需求及新興療法的未來成就
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Global Chronic Obstructive Pulmonary Disease (COPD) Market Outlook

Thelansis's "Global Chronic Obstructive Pulmonary Disease (COPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Obstructive Pulmonary Disease treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Chronic Obstructive Pulmonary Disease (COPD) Overview

Chronic Obstructive Pulmonary Disease (COPD) is a major global cause of chronic morbidity and mortality, currently ranking among the leading causes of death worldwide. The disease is characterized by persistent airflow limitation resulting from chronic inflammation, airway remodeling, and progressive destruction of lung parenchyma.

Pathophysiologically, COPD involves narrowing of small airways, loss of alveolar attachments, and reduced lung elasticity, which impair airflow, particularly during exhalation. This leads to air trapping, reduced gas exchange, and progressive respiratory dysfunction.

Diagnosis is confirmed using spirometry, with a post-bronchodilator FEV1/FVC ratio <0.70 indicating airflow obstruction. However, disease burden is not solely determined by airflow limitation; symptom severity (e.g., dyspnea, cough) and frequency of exacerbations play a critical role in clinical assessment.

Modern COPD management follows a multidimensional approach, combining spirometric classification with symptom burden and exacerbation risk to guide therapy. Treatment includes bronchodilators (LABA/LAMA), inhaled corticosteroids (ICS), and supportive care, aimed at reducing symptoms, preventing exacerbations, and improving quality of life.

Key Highlights

• COPD is a high-prevalence, chronic respiratory disease with significant global mortality burden
• US prevalent population expected to grow from ~28.1M to ~33.0M (~1.6% CAGR)

Market Overview

• Spain (mild-to-moderate segment) market projected to grow from ~$219M to ~$231M (~0.5% CAGR)
• Growth remains modest, driven by generic inhalation therapies and stable disease prevalence, with limited breakthrough innovation

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• SMSbiotech
• Haisco Pharmaceutical Group Co., Ltd.
• GlaxoSmithKline
• Hoffmann-La Roche
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Genentech, Inc.
• Verona Pharma plc
• Keymed Biosciences Co.Ltd
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Reistone Biopharma Company Limited
• Sanofi
• Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
• Eurofarma Laboratorios S.A.
• AstraZeneca
• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
• Regend Therapeutics
• Nuance Pharma (shanghai) Co., Ltd
• Upstream Bio Inc.
• Bambusa Therapeutics
• Areteia Therapeutics
• Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
• Anhui Hemay Pharmaceutical Co., Ltd
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Mabwell (Shanghai) Bioscience Co., Ltd.
• S-INFINITY Pharmaceuticals Co., Ltd
• Merck Sharp & Dohme LLC
• Mesoblast, Inc.
• Joincare Pharmaceutical Group Industry Co., Ltd
• Ganzhou Hemay Pharmaceutical Co., Ltd
• Chiesi Farmaceutici S.p.A.
• Bun Yao Biotechnology Co., Ltd
• Generate Biomedicines
• Rise Therapeutics LLC
• AeroRx Therapeutics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)